← Leaderboards
Elizabeth C Dees
University Of North Carolina Chapel Hill
$8,557,163
Attributed
$13,437,874
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,437,874 · 16
By mechanism
UM1$6,775,451 · 1
P30$5,124,573 · 3
K23$615,130 · 1
UG1$454,679 · 1
R21$403,540 · 1
M01$64,501 · 9
Top collaborators
- James L Abbruzzese6 shared
- Andrea Wang-Gillam6 shared
- Herbert I Hurwitz2 shared
- Albert Craig Lockhart2 shared
- Lisa A Carey1 shared
- Ellen L Jones1 shared
- Matthew I Milowsky1 shared
- Linda Van Le1 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- James Patrick Morken$12,498,941
- Karen L Mohlke$33,842,140
- Wanda K O'Neal$8,008,262
- Terry A Van Dyke$19,016,013
- Michael T. Crimmins$6,748,855
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelClinical TrialsEnrollmentClinical ResearchBaseCancer CenterInnovationFundingProgramsMalignant NeoplasmsMemberLeadershipImmunotherapySiteFacultyGrantCancer Center Support GrantComprehensive Cancer CenterLaboratoriesScienceProtocols DocumentationDrug DevelopmentGenomicsCancer Patient
Grant awards (49)
UNC Lead Academic Participating Site$454,679
UG1 · FY2025 · CA
Clinical Protocol and Data Management (Core 018)$689,776
P30 · FY2020 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)$287,368
P30 · FY2020 · CA · contact PI
Clinical Research Program (Program 6)$56,890
P30 · FY2020 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$1,702,907
UM1 · FY2019 · CA
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)$715,167
UM1 · FY2019 · CA
Clinical Protocol and Data Management (Core 018)$668,602
P30 · FY2019 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)$278,546
P30 · FY2019 · CA · contact PI
Clinical Research Program (Program 6)$55,142
P30 · FY2019 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$1,703,461
UM1 · FY2018 · CA
Clinical Protocol and Data Management (Core 018)$689,774
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)$287,365
P30 · FY2018 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$170,500
UM1 · FY2018 · CA
Clinical Research Program (Program 6)$56,887
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)$2,968
P30 · FY2018 · CA · contact PI
Clinical Research Program (Program 6)$2,968
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management (Core 018)$2,968
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management (Core 018)$2,102
P30 · FY2018 · CA · contact PI
Clinical Research Program (Program 6)$2,101
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)$2,101
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management (Core 018)$1,366
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)$1,366
P30 · FY2018 · CA · contact PI
Clinical Research Program (Program 6)$1,366
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management (Core 018)$676,693
P30 · FY2017 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)$281,916
P30 · FY2017 · CA · contact PI
Clinical Research Program (Program 6)$55,809
P30 · FY2017 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$891,969
UM1 · FY2016 · CA
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$884,114
UM1 · FY2016 · CA
Clinical Protocol and Data Management (Core 018)$680,746
P30 · FY2016 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)$283,606
P30 · FY2016 · CA · contact PI
Clinical Research Program (Program 6)$56,147
P30 · FY2016 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$201,163
UM1 · FY2015 · CA
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$506,170
UM1 · FY2014 · CA
CLINICAL TRIAL: LCCC 0509: A TWO-ARM PHASE I DOSE ESCALATION TRIAL OF VINFLUNINE$15,457
M01 · FY2008 · RR · contact PI
Phase I Radiosensitization Study of GW572016 in Recurrent Breast Cancer$198,801
R21 · FY2007 · CA · contact PI
LCCC 0509: A TWO-ARM PHASE I DOSE ESCALATION TRIAL OF VINFLUNINE$10,692
M01 · FY2007 · RR · contact PI
CALGB 60301: SORAFENIB FOR SOLID TUMORS AND HAM MALIGNANCIES$2,064
M01 · FY2007 · RR · contact PI
COMBINATION OF PEGYLATED LIPOSOMAL DOXIL WITH PS-341 IN PATIENTS WITH MALIGNANC$1,501
M01 · FY2007 · RR · contact PI
MLN8054, AURORA A KINASE INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMOR$750
M01 · FY2007 · RR · contact PI
Phase I Radiosensitization Study of GW572016 in Recurrent Breast Cancer$204,739
R21 · FY2006 · CA · contact PI
P450 PHENOTYPE AND CHEMOTHERAPY TOXICITY IN THE ELDERLY$123,490
K23 · FY2006 · RR · contact PI
CALGB 60301: SORAFENIB FOR SOLID TUMORS AND HAM MALIGNANCIES$17,594
M01 · FY2006 · RR · contact PI
P450 PHENOTYPE AND CHEMOTHERAPY TOXICITY IN THE ELDERLY$122,997
K23 · FY2005 · RR
COMBINATION OF PEGYLATED LIPOSOMAL DOXIL WITH PS-341 IN PATIENTS WITH MALIGNANC$3,141
M01 · FY2005 · RR
P450 PHENOTYPE AND CHEMOTHERAPY TOXICITY IN THE ELDERLY$122,517
K23 · FY2004 · RR
Relationship Between Paclitaxel Pharmacokinetics and Phenotypic Markers$13,019
M01 · FY2004 · RR
NSABP P-1: Trial to Determine Worth of Tamoxifen for Preventing Breast Cancer.$283
M01 · FY2004 · RR
P450 PHENOTYPE AND CHEMOTHERAPY TOXICITY IN THE ELDERLY$122,051
K23 · FY2003 · RR
P450 PHENOTYPE AND CHEMOTHERAPY TOXICITY IN THE ELDERLY$124,075
K23 · FY2002 · RR